Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers

被引：4
|
作者：
Proulx, L. [1 ]
Bourgault, B. [1 ]
Chauret, N. [1 ]
Larouche, R. [2 ]
Tanguay, M. [2 ]
Thibert, R. [1 ]
机构：
[1] ViroChem Pharma Inc, Laval, PQ, Canada
[2] Anapharm A PharmaNet Co, Montreal, PQ, Canada
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60856-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
854
引用
收藏
页码：S320 / S321
页数：2
相关论文
共 50 条
  • [31] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [32] A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS
    Patti, J.
    Matson, M.
    Boehlecke, B.
    Barry, A.
    Wenzel, E.
    Pentikis, H.
    Alam, J.
    Henson, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S187 - S187
  • [33] Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects
    Tamaki, Sekihiro
    Shibata, Tsutomu
    Hunt, Thomas
    Gerhardt, Barbara
    Yamada, Hiroyuki
    Pai, Sudhakar M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (03): : 371 - 384
  • [34] Safety, tolerability, pharmacokinetic profile and pharmacodynamic characteristics of sabiporide, a novel cardioselective NHE-inhibitor, after oral and IV single doses in healthy male volunteers.
    Klueglich, M
    Rathgen, K
    Nehmiz, G
    Trommeshauser, D
    Seidler, R
    Rathgen, K
    Nehmiz, G
    Trommeshauser, D
    Seidler, R
    Roberts, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1056 - 1056
  • [35] Pharmacokinetic and safety profile CTP-692 (deuterated D-serine) following administration of single and multiple ascending doses in healthy volunteers
    Uttamsingh, V.
    McIntyre, E.
    Vedananda, S.
    Brummel, C. L.
    Braman, V.
    Cassella, J. V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S450 - S451
  • [36] Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study
    Desch, Michael
    Huennemeyer, Andreas
    Suessmuth, Sigurd D.
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S379 - S379
  • [37] Multiple Rising Doses of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability
    Goettel, Markus
    Herich, Lena
    Wiebe, Sabrina
    Fuertig, Rene
    Sharma, Vikas
    Goettel, Markus
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S417 - S418
  • [38] PHASE-I STUDY OF CILOSTAZOL - SAFETY EVALUATION AT INCREASING SINGLE DOSES IN HEALTHY-VOLUNTEERS
    NIKI, T
    MORI, H
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1985, 35-2 (7A): : 1173 - 1185
  • [39] PHASE I TRIAL OF PYRAGREL, A NOVEL THROMBOXANE SYNTHETASE INHIBITOR, TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS.
    Zou, C.
    Huang, J.
    Pei, Q.
    Yang, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S78 - S78
  • [40] BCX4161, An Oral Kallikrein Inhibitor: Safety and Pharmacokinetic Results Of a Phase 1 Study In Healthy Volunteers
    Collis, Phil
    Cornpropst, Melanie
    Collier, Jo
    Sheridan, William
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB39 - AB39
12345